A Study of Galcanezumab in Healthy Participants

NCT02576951 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

178

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Galcanezumab
DRUG: Placebo

Sponsor

Eli Lilly and Company